logo

Aradigm Corp (ARDM)



Trade ARDM now with
  Date
  Headline
8/14/2018 8:08:46 AM Aradigm Q2 Net Loss $3.8 Mln Or $0.25/shr Vs. Net Income $1.0 mln Or $0.07/shr Last Year
4/5/2018 8:23:46 AM Aradigm Announces EMA Has Completed Its Validation Of MAA Submission For Linhaliq
3/23/2018 8:04:02 AM Aradigm Q4 Net Loss $4.2 Mln Or $0.28/Shr Vs Loss Of $7.9 Mln Or $0.54/Shr Last Year
3/9/2018 8:03:53 AM Aradigm Submits MAA To EMA For EU Marketing Approval Of Linhaliq In Non-Cystic Fibrosis Bronchiectasis
1/29/2018 7:03:00 AM Aradigm Receives Complete Response Letter From FDA For Linhaliq NDA
1/11/2018 6:59:44 AM Aradigm Trading Halted; Pending News
12/29/2017 5:39:58 AM In The Spotlight: Aradigm Corp
12/1/2017 7:04:44 AM Aradigm Announces FDA Advisory Committee Meeting For Linhaliq Scheduled For January 11, 2018
11/2/2017 7:30:23 AM Aradigm Q3 Loss/shr $0.26 Vs. Loss/shr $0.55 Last Year
10/10/2017 7:02:21 AM Aradigm Regains Compliance With NASDAQ Listing Requirements
9/25/2017 7:05:43 AM Aradigm Announces FDA Acceptance Of NDA For Linhaliq With Priority Review Status
8/15/2017 7:04:31 AM Aradigm Gets NIH Grant To Investigate Treatment Of PNTM Infections With Linhaliq
8/10/2017 7:13:26 AM Aradigm Q2 EPS $0.07 Vs $0.59 Last Year